Post-corporate makeover, Immunocore draws $130M in series B March 2, 2020 By Nuala Moran No Comments LONDON – Immunocore Ltd. has closed a series B round that will bring in more than $130 million, breathing fresh energy into its T-cell receptor programs in cancer and extending the reach of the technology into infectious and autoimmune diseases.Read More